Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE:TEVA) is facing serious charges after EU antitrust regulators went to court. The body on Monday accused the top provider of conniving with Cephalon in a bid to put in place delays on the sale of a cheaper generic version of a sleep disorder drug. People familiar with the matter have outlined that Teva may pay a huge fine.

This is not the first company that the EU is going after for this. Over the years, it has pushed a series of companies to the edge leading them to pay huge fines including. Johnson & Johnson (NYSE:JNJ).

According to the claims, a number of European consumers were negatively impacted considering to the tune of billions of euros.

It was a deal that targeted lifting a lawsuit over alleged infringement of Cephalon’s patents. The process involved a series of cash payments from Cephalon, though in 2011 Teva acquired it. Some analysts have discussed the matter citing that the delays hiked prices of the drug Modafini.

While speaking to a number of news reporters , one of the executives working with the EU said, “The patent settlement agreement between Cephalon and Teva may have caused substantial harm to EU patients and health service budgets. We do not believe that Cephalon and Teva entered into any anti-competitive behavior.”

Teva continuously objected to the way the body had been carrying out the analysis of different deals. However it is important to outline that doing business is a matter that is from time to time marred by numerous challenges. It shouldn’t define the end for any top provider. The company is looking forward to moving smoothly through the controversy and hopes that soon it will be able to go back to its normal business operations according to Yahoo.